NYSE:ENOV Enovis (ENOV) Stock Forecast, Price & News $51.66 -0.22 (-0.42%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$51.51▼$52.2750-Day Range$51.67▼$65.5052-Week Range$43.88▼$66.71Volume234,233 shsAverage Volume393,417 shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$65.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Enovis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside26.4% Upside$65.29 Price TargetShort InterestBearish5.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 8 Articles This WeekInsider TradingSelling Shares$14,674 Sold Last QuarterProj. Earnings Growth16.81%From $2.26 to $2.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector203rd out of 968 stocksSurgical Appliances & Supplies Industry6th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingEnovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.29, Enovis has a forecasted upside of 26.4% from its current price of $51.67.Amount of Analyst CoverageEnovis has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.42% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Enovis has recently increased by 10.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENOV. Previous Next 2.8 News and Social Media Coverage News SentimentEnovis has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Enovis this week, compared to 3 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,674.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enovis are expected to grow by 16.81% in the coming year, from $2.26 to $2.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -20.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enovis (NYSE:ENOV) StockEnovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Read More ENOV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENOV Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comEnovis Co. (NYSE:ENOV) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 21, 2023 | finance.yahoo.comBoomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI RevolutionSeptember 22, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 18, 2023 | finance.yahoo.comEnovis Debuts New Foot & Ankle Offerings at the AOFAS Annual MeetingSeptember 7, 2023 | finance.yahoo.comShould You Invest in Enovis Corporation (ENOV)?August 8, 2023 | finance.yahoo.comEnovis to Participate in Upcoming Investor ConferencesAugust 3, 2023 | finance.yahoo.comEnovis Corporation (ENOV) Outperformed on Improving Market ConditionsAugust 3, 2023 | finance.yahoo.comEnovis Announces Second Quarter 2023 Results and Raises Full-Year OutlookSeptember 22, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.August 3, 2023 | finance.yahoo.comEnovis (ENOV) Q2 Earnings and Revenues Beat EstimatesJuly 18, 2023 | msn.comEnovis Corporation: Things Are Looking Good As Guidance Is RaisedJuly 11, 2023 | finance.yahoo.comEnovis to Host Second Quarter 2023 Results Conference Call on August 3rdJuly 10, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)July 6, 2023 | finance.yahoo.comEnovis™ Recognized as One of America’s Greatest Workplaces 2023 by NewsweekJuly 3, 2023 | finance.yahoo.comWhat Makes Enovis Corporation (ENOV) a Good Investment Choice?June 29, 2023 | finanznachrichten.deEnovis Corporation: Enovis Completes Acquisition of NovastepJune 28, 2023 | msn.comNeedham starts Enovis at buy; cites market share growth, valuationJune 28, 2023 | finance.yahoo.comEnovis™ Completes Acquisition of Novastep®June 26, 2023 | markets.businessinsider.comEnovis Above-Market Growth Potential Surge Would Come from Market Share Gains and Accretive Acquisitions: AnalystJune 2, 2023 | finance.yahoo.comEnovis to Participate in Investor Conferences in JuneMay 22, 2023 | finance.yahoo.comEnovis (NYSE:ENOV) shareholders are still up 1.1% over 5 years despite pulling back 4.3% in the past weekMay 17, 2023 | marketwatch.comCatheter Stabilization Device Market Forthcoming Trends and Share Analysis by 2031May 17, 2023 | marketwatch.comSurgical Bone Growth Stimulator Market Share, Size, Financial Summaries Analysis from 2023-2029 with Top Players are Orthofix, Enovis, ZimVieMay 12, 2023 | msn.comLooking Into Enovis's Return On Invested CapitalMay 12, 2023 | msn.comEnovis upgraded at Wells Fargo on valuationMay 5, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on Enovis (ENOV)May 4, 2023 | finance.yahoo.comQ1 2023 Enovis Corp Earnings CallSee More Headlines Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address ENOV Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:ENOV CUSIPN/A CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees6,800Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.29 High Stock Price Forecast$70.00 Low Stock Price Forecast$57.00 Forecasted Upside/Downside+26.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E Ratio22.85 P/E GrowthN/ANet Income$-13,290,000.00 Net Margins-8.52% Pretax Margin-8.00% Return on Equity3.74% Return on Assets2.95% Debt Debt-to-Equity Ratio0.12 Current Ratio2.51 Quick Ratio1.23 Sales & Book Value Annual Sales$1.56 billion Price / Sales1.80 Cash Flow$6.18 per share Price / Cash Flow8.35 Book Value$63.71 per share Price / Book0.81Miscellaneous Outstanding Shares54,540,000Free Float51,758,000Market Cap$2.82 billion OptionableOptionable Beta2.05 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Matthew L. Trerotola (Age 56)CEO & Chairman Comp: $5.12MMr. Brady R. Shirley (Age 57)Pres, COO & Director Comp: $3.34MMs. Patricia A. Lang (Age 64)Sr. VP & Chief HR Officer Comp: $1.59MMr. Daniel A. Pryor (Age 55)Exec. VP of Strategy & Bus. Devel. Comp: $2.08MMr. Phillip Benjamin Berry (Age 44)Sr. VP & CFO Mr. John Kleckner (Age 46)VP, Controller & Chief Accounting Officer Derek LeckowVP of Investor RelationsMr. Bradley J. Tandy (Age 64)Sr. VP & Gen. Counsel Katie SweetVP of Corp. CommunicationBrian P. HaniganSec.More ExecutivesKey CompetitorsEstablishment LabsNASDAQ:ESTAAvanos MedicalNYSE:AVNSSmith & NephewNYSE:SNNAxonicsNASDAQ:AXNXAzentaNASDAQ:AZTAView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 9,692 shares on 8/23/2023Ownership: 0.018%Virginia Retirement Systems ET ALBought 22,500 shares on 8/22/2023Ownership: 0.041%California State Teachers Retirement SystemSold 1,011 shares on 8/21/2023Ownership: 0.111%Teachers Retirement System of The State of KentuckyBought 872 shares on 8/21/2023Ownership: 0.016%Osaic Holdings Inc.Bought 5,270 shares on 8/21/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ENOV Stock - Frequently Asked Questions Should I buy or sell Enovis stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENOV shares. View ENOV analyst ratings or view top-rated stocks. What is Enovis' stock price forecast for 2023? 6 analysts have issued 12-month price targets for Enovis' shares. Their ENOV share price forecasts range from $57.00 to $70.00. On average, they anticipate the company's share price to reach $65.29 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts. How have ENOV shares performed in 2023? Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV shares have decreased by 3.5% and is now trading at $51.64. View the best growth stocks for 2023 here. Are investors shorting Enovis? Enovis saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,690,000 shares, an increase of 10.2% from the August 15th total of 2,440,000 shares. Based on an average daily trading volume, of 357,800 shares, the short-interest ratio is currently 7.5 days. Currently, 5.4% of the shares of the stock are sold short. View Enovis' Short Interest. When is Enovis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ENOV earnings forecast. How were Enovis' earnings last quarter? Enovis Co. (NYSE:ENOV) issued its earnings results on Thursday, August, 3rd. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.08. The business had revenue of $428.50 million for the quarter, compared to analysts' expectations of $420.06 million. Enovis had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 3.74%. The company's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.59 earnings per share. What ETFs hold Enovis' stock? ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Value ETF (RFV) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI). What guidance has Enovis issued on next quarter's earnings? Enovis updated its FY 2023 earnings guidance on Friday, September, 22nd. The company provided EPS guidance of $2.22-$2.36 for the period, compared to the consensus earnings per share estimate of $2.31. The company issued revenue guidance of -. What is Enovis' stock symbol? Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV." Who are Enovis' major shareholders? Enovis' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.10%), Dimensional Fund Advisors LP (5.44%), Diamond Hill Capital Management Inc. (4.05%), Thrivent Financial for Lutherans (3.25%), State Street Corp (2.81%) and Durable Capital Partners LP (2.79%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enovis' stock price today? One share of ENOV stock can currently be purchased for approximately $51.64. How much money does Enovis make? Enovis (NYSE:ENOV) has a market capitalization of $2.82 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. How many employees does Enovis have? The company employs 6,800 workers across the globe. How can I contact Enovis? Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001. This page (NYSE:ENOV) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.